The senescence hypothesis of disease progression in alzheimer disease: An Integrated matrix of disease pathways for FAD and SAD

Molecular Neurobiology

Volumn 48, Issue 3, 2013, Pages 556-570

  Hunter, Sally ^a   Arendt, Thomas ^b   Brayne, Carol ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Paul Flechsig Inst for Brain Res   (Germany)

Author keywords

Alzheimer disease; Amyloid precursor protein; Amyloid beta protein; Presenilin; Senescence

Indexed keywords

ACETYLCHOLINE; AMYLOID; ERYTHROPOIETIN; FREE RADICAL; GAMMA INTERFERON; GAMMA SECRETASE; GLUTAMIC ACID; HEAT SHOCK PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; NICASTRIN; NITROGEN; PRESENILIN; TUMOR NECROSIS FACTOR ALPHA;

AGE; AGING; ALZHEIMER DISEASE; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL FATE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; COPY NUMBER VARIATION; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; ENVIRONMENTAL FACTOR; FUNCTIONAL STATUS; GENE EXPRESSION; GENE MUTATION; HEREDITY; HUMAN; HYPOTHESIS; IMMUNE SYSTEM; INFLAMMATION; MACROPHAGE; MICROGLIA; MUTATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REDOX STRESS; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE;

AGING; ALZHEIMER DISEASE; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; NERVE DEGENERATION; NEURONS;

EID: 84887995472     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8445-3     Document Type: Review

References (252)

1. Morris JC et al (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39(9):1159-1165
2. Mirra SS et al (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4):479-486
3. Koudinov AR, Koudinova NV (2005) Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J Neurol Sci 229-230:233-240
4. Poirier J (2005) Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 26(3):355-361
5. Lane RM, Farlow MR (2005) Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 46(5):949-968
6. Eckert A et al (2003) Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 66(8):1627-1634
7. Hoyer S (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm 109(7-8):991-1002
8. Hoyer S (2004) Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 541:135-152
9. Bartus RT et al (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558):408-414
10. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6(3):337-350
11. Bojarski L, Herms J, Kuznicki J (2008) Calcium dysregulation in Alzheimer's disease. Neurochem Int 52(4-5):621-633
12. Arendt T (2003) Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog Neurobiol 71(2-3):83-248
13. Fotuhi M, Hachinski V, Whitehouse PJ (2009) Changing perspectives regarding late-life dementia. Nat Rev Neurol 5(12):649-658
14. Hunter S, Friedland RP, Brayne C (2010) Time for a change in the research paradigm for Alzheimer's disease: the value of a chaotic matrix modeling approach. CNS Neurosci Ther 16(4):254-262
15. Hunter S, Brayne C (2012) Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems. Alzheimers Res Ther 4(2):10
16. Herrup K (2010) Reimagining Alzheimer's disease - an age-based hypothesis. J Neurosci 30(50):16755-16762
17. Zekanowski C et al (2004) Genetic aspects of Alzheimer's disease. Acta Neurobiol Exp (Wars) 64(1):19-31
18. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054):184-185
19. Bondareff W et al (1987) Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. Arch Gen Psychiatry 44(5):412-417
20. Mann DM, Yates PO, Marcyniuk B (1988) Pathologic heterogeneity of Alzheimer's disease. Arch Gen Psychiatry 45(10):962-963
21. Walker LC, Rosen RF, Levine H III (2008) Diversity of Abeta deposits in the aged brain: a window on molecular heterogeneity? Rom J Morphol Embryol 49(1):5-11
22. Matthews FE et al (2009) Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6(11):e1000180
23. MRC-CFAS (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357(9251):169-175
24. Brayne C (2007) The elephant in the room - healthy brains in later life, epidemiology and public health. Nat Rev Neurosci 8(3):233-239
25. Sikora E et al (2011) Impact of cellular senescence signature on ageing research. Ageing Res Rev 10(1):146-152
26. Vargas J et al (2012) Senescence; an endogenous anticancer mechanism. Front Biosci 17:2616-2643
27. Ohtani N et al (2012) Cellular senescence: a double-edged sword in the fight against cancer. Exp Dermatol 21(Suppl 1):1-4
28. Shay JW, Roninson IB (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23(16):2919-2933
29. Bursch W et al (2000) Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci 113(Pt 7):1189-1198
30. Moreira PI et al (2010) Autophagy in Alzheimer's disease. Expert Rev Neurother 10(7):1209-1218
31. Caballero B, Coto-Montes A (2012) An insight into the role of autophagy in cell responses in the aging and neurodegenerative brain. Histol Histopathol 27(3):263-275
32. Mastroeni D et al (2011) Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 32(7):1161-1180
33. Davalos AR et al (2010) Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 29(2):273-283
34. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45
35. Clark IA, Alleva LM, Vissel B (2010) The roles of TNF in brain dysfunction and disease. Pharmacol Ther 128(3):519-548
36. Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer's disease, role of cytokines. Sci World J 2012:756357
37. Rosales-Corral S et al (2004) Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-beta onto the hippocampus in vivo. J Neuroimmunol 150(1-2):20-28
38. Lovell MA, Markesbery WR (2007) Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35(22):7497-7504
39. Gartner U et al (1995) Induction of p21ras in Alzheimer pathology. Neuroreport 6(10):1441-1444
40. Arendt T et al (1996) Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport 7(18):3047-3049
41. Arendt T, Holzer M, Gartner U (1998) Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease. J Neural Transm 105(8-9):949-960
42. Luth HJ et al (2000) Aberrant expression of nNOS in pyramidal neurons in Alzheimer's disease is highly co-localized with p21ras and p16INK4a. Brain Res 852(1):45-55
43. Alves da Costa C et al (2006) Presenilin-dependent gamma-secretase- mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 26(23):6377-6385
44. Gartner U, Holzer M, Arendt T (1999) Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience 91(1):1-5
45. Hoozemans JJ et al (2005) Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J Neuroinflammation 2:27
46. Lee HG et al (2009) Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int 54(2):84-88
47. Arendt T (2004) Neurodegeneration and plasticity. Int J Dev Neurosci 22(7):507-514
48. Butterfield DA, Sultana R (2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 12(1):61-72
49. Butterfield DA, Sultana R (2008) Identification of 3-nitrotyrosine- modified brain proteins by redox proteomics. Methods Enzymol 440:295-308
50. Law A, Gauthier S, Quirion R (2001) Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res Brain Res Rev 35(1):73-96
51. Marques CA et al (2003) Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J Biol Chem 278(30):28294-28302
52. Gibson GE, Huang HM (2002) Oxidative processes in the brain and non-neuronal tissues as biomarkers of Alzheimer's disease. Front Biosci 7:d1007-d1015
53. Zhu X et al (2004) Oxidative stress signalling in Alzheimer's disease. Brain Res 1000(1-2):32-39
54. Zhu X et al (2005) Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 31(1-3):205-217
55. Butterfield DA et al (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22(2):223-232
56. Perry G et al (1998) Reactive oxygen species mediate cellular damage in alzheimer disease. J Alzheimers Dis 1(1):45-55
57. Nunomura A et al (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60(8):759-767
58. McGeer EG, Klegeris A, McGeer PL (2005) Inflammation, the complement system and the diseases of aging. Neurobiol Aging 26(Suppl 1):94-97
59. Lee HP et al (2010) Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 10(7):1201-1208
60. Leuner K et al (2007) Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease. J Neural Transm Suppl 72:207-215
61. Hirai K et al (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21(9):3017-3023
62. Aliev G et al (2004) Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4(5-6):649-663
63. Mattson MP (2002) Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease. J Neurovirol 8(6):539-550
64. Hamel E et al (2008) Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp Physiol 93(1):116-120
65. de la Torre JC (2000) Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord 14(Suppl 1):S72-S81
66. Aliev G et al (2003) Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res 5(7):491-504
67. Mattson MP, Pedersen WA (1998) Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Dev Neurosci 16(7-8):737-753
68. Matos M et al (2008) Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156(4):898-910
69. Chong ZZ, Li F, Maiese K (2005) Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 75(3):207-246
70. Yeoman M, Scutt G, Faragher R (2012) Insights into CNS ageing from animal models of senescence. Nat Rev Neurosci 13(6):435-445
71. Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 545(1):39-50
72. Lee HG et al (2006) Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 3(1):75-80
73. Bishop GM, Robinson SR (2002) The amyloid hypothesis: let sleeping dogmas lie? Neurobiol Aging 23(6):1101-1105
74. Butterfield DA, Boyd-Kimball D (2004) Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 14(4):426-432
75. Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24(5):981-990
76. Ladelfa MF et al (2011) Interaction of p53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production. Antioxid Redox Signal 15(6):1749-1761
77. Melo A et al (2011) Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxidative Med Cell Longev 2011:467180
78. Akiyama H et al (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21(3):383-421
79. Popp J et al (2009) Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 43(8):749-753
80. D'Andrea MR (2003) Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease. Brain Res 982(1):19-30
81. Shen Y, Meri S (2003) Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol 70(6):463-472
82. Giunta B et al (2008) Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 5:51
83. Pizza V et al (2011) Neuroinflammation and ageing: current theories and an overview of the data. Rev Recent Clin Trials 6(3):189-203
84. Hoozemans JJ et al (2006) Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 24(2-3):157-165
85. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12(9):1005-1015
86. Szekely CA, Town T, Zandi PP (2007) NSAIDs for the chemoprevention of Alzheimer's disease. Subcell Biochem 42:229-248
87. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28(5):639-647
88. Malm T et al (2010) The role and therapeutic potential of monocytic cells in Alzheimer's disease. Glia 58(8):889-900
89. Ito S et al (2005) Amyloid-beta peptides induce cell proliferation and macrophage colony-stimulating factor expression via the PI3-kinase/Akt pathway in cultured Ra2 microglial cells. FEBS Lett 579(9):1995-2000
90. Lee CY, Landreth GE (2010) The role of microglia in amyloid clearance from the AD brain. J Neural Transm 117(8):949-960
91. Kakimura J et al (2002) Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J 16(6):601-603
92. Shang YC et al (2012) Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 4(3):187-201
93. Wegiel J et al (2004) Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. Brain Res 1022(1-2):19-29
94. Floden AM, Li S, Combs CK (2005) Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25(10):2566-2575
95. von Bernhardi R (2007) Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox Res 12(4):215-232
96. Morgan D et al (2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64(9):743-753
97. Merlini M et al (2011) Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol 122(3):293-311
98. Wu B et al (2009) RAGE, LDL receptor, and LRP1 expression in the brains of SAMP8. Neurosci Lett 461(2):100-105
99. Utter S et al (2008) Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. J Neuropathol Exp Neurol 67(9):842-856
100. Deane R, Sagare A, Zlokovic BV (2008) The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des 14(16):1601-1605
101. Bruinsma IB et al (2010) Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta(1-40)-mediated cell death. Brain Res 1315:169-180
102. Fagan AM, Holtzman DM (2000) Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo. Microsc Res Tech 50(4):297-304
103. Wilhelmus MM et al (2007) Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 171(6):1989-1999
104. Deane R et al (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118(12):4002-4013
105. Blasko I et al (2000) Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis 7(6 Pt B):682-689
106. Nagele RG et al (2003) Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971(2):197-209
107. Hawkes CA, McLaurin J (2009) Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 106(4):1261-1266
108. Ho GJ et al (2005) Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 4(2):247-256
109. Beglopoulos V et al (2004) Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J Biol Chem 279(45):46907-46914
110. Laskowitz DT et al (2000) Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 41(4):613-620
111. Zhang H, Wu LM, Wu J (2011) Cross-talk between apolipoprotein E and cytokines. Mediat Inflamm 2011:949072
112. Poirier J (1999) Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Psychiatry Neurosci 24(2):147-153
113. Nelson TJ, Alkon DL (2005) Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Trans 33(Pt 5):1033-1036
114. Bentley NM et al (2002) Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges. Biochem J 366(Pt 1):273-279
115. Michikawa M et al (2000) Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74(3):1008-1016
116. Lahiri DK, Sambamurti K, Bennett DA (2004) Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 25(5):651-660
117. Kivipelto M et al (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137(3):149-155
118. Tokuda T et al (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J 348(Pt 2):359-365
119. Tamamizu-Kato S et al (2008) Interaction with amyloid beta peptide compromises the lipid binding function of apolipoprotein E. Biochemistry 47(18):5225-5234
120. Zerbinatti CV, Bu G (2005) LRP and Alzheimer's disease. Rev Neurosci 16(2):123-135
121. Bu G, Cam J, Zerbinatti C (2006) LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci 1086:35-53
122. Jaeger S, Pietrzik CU (2008) Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 5(1):15-25
123. Pietrzik CU et al (2002) The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 21(21):5691-5700
124. Lleo A et al (2005) Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. J Biol Chem 280(29):27303-27309
125. Jiang Q et al (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58(5):681-693
126. Attems J et al (2010) Capillary CAA and perivascular Abeta-deposition: two distinct features of Alzheimer's disease pathology. J Neurol Sci 299(1-2):155-162
127. Mazur-Kolecka B et al (2003) The effect of oxidative stress on accumulation of apolipoprotein E3 and E4 in a cell culture model of beta-amyloid angiopathy (CAA). Brain Res 983(1-2):48-57
128. Holtzman DM (2001) Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J Mol Neurosci 17(2):147-155
129. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1:CD005593
130. Thomas SJ, Grossberg GT (2009) Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 4:367-377
131. Lanctot KL, Herrmann N, LouLou MM (2003) Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci 28(1):13-26
132. Frolich L (2002) The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings. J Neural Transm 109(7-8):1003-1013
133. Brousseau G, Rourke BP, Burke B (2007) Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. Exp Clin Psychopharmacol 15(6):546-554
134. Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 113(11):1625-1644
135. Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221(2):555-563
136. Mufson EJ et al (2003) Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26(4):233-242
137. Herholz K (2008) Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35(Suppl 1):S25-S29
138. Herholz K, Weisenbach S, Kalbe E (2008) Deficits of the cholinergic system in early AD. Neuropsychologia 46(6):1642-1647
139. Davis KL et al (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281(15):1401-1406
140. Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821-827
141. Mesulam M et al (2004) Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55(6):815-828
142. Goekoop R et al (2006) Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - a pharmacological fMRI study. Brain 129(Pt 1):141-157
143. Schaeffer EL, Gattaz WF (2008) Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berlin) 198(1):1-27
144. Lee HG et al (2005) Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 11(4):164-169
145. Bonda DJ et al (2011) A novel perspective on tau in Alzheimer's disease. Curr Alzheimer Res 8(6):639-642
146. Rankin CA, Gamblin TC (2008) Assessing the toxicity of tau aggregation. J Alzheimers Dis 14(4):411-416
147. Kosik KS, Shimura H (2005) Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta 1739(2-3):298-310
148. Khurana V et al (2012) A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell 11(2):360-362
149. Souter S, Lee G (2010) Tubulin-independent tau in Alzheimer's disease and cancer: implications for disease pathogenesis and treatment. Curr Alzheimer Res 7(8):697-707
150. Bleys RL, Cowen T (2001) Innervation of cerebral blood vessels: morphology, plasticity, age-related, and Alzheimer's disease-related neurodegeneration. Microsc Res Tech 53(2):106-118
151. Lin W et al (2012) Role of alpha7-nicotinic acetylcholine receptor in normal and cancer stem cells. Curr Drug Targets 13(5):656-665
152. Dasgupta P, Chellappan SP (2006) Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 5(20):2324-2328
153. Kalaria RN (1999) The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 893:113-125
154. Brown WR, Thore CR (2011) Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 37(1):56-74
155. Farkas E, Luiten PG (2001) Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64(6):575-611
156. Fernando MS et al (2006) White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 37(6):1391-1398
157. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118(1):103-113
158. Thal DR et al (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol 115(6):599-609
159. Thal DR et al (2002) Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61(3):282-293
160. Thal DR et al (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol 120(2):169-183
161. Weller RO et al (2009) Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117(1):1-14
162. Wisniewski HM et al (2000) Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci 903:6-18
163. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28(4):202-208
164. Donnini S et al (2010) Abeta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis. FASEB J 24(7):2385-2395
165. Boscolo E et al (2007) Beta amyloid angiogenic activity in vitro and in vivo. Int J Mol Med 19(4):581-587
166. Mattson MP (2006) Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal 8(11-12):1997-2006
167. Verri M et al (2012) Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Int J Immunopathol Pharmacol 25(2):345-353
168. Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp Gerontol 42(1-2):10-21
169. Erol A (2010) Are paradoxical cell cycle activities in neurons and glia related to the metabolic theory of Alzheimer's disease? J Alzheimers Dis 19(1):129-135
170. Feng Z (2010) p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol 2(2):a001057
171. Goberdhan DC, Boyd CA (2009) mTOR: dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans 37(Pt 1):213-216
172. Sofi F et al (2011) Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med 269(1):107-117
173. Maiorana A et al (2003) Exercise and the nitric oxide vasodilator system. Sports Med 33(14):1013-1035
174. Radak Z et al (2007) Effects of exercise on brain function: role of free radicals. Appl Physiol Nutr Metab 32(5):942-946
175. Ma Q (2008) Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. Neurosci Bull 24(4):265-270
176. Barrientos RM et al (2011) Little exercise, big effects: reversing aging and infection-induced memory deficits, and underlying processes. J Neurosci 31(32):11578-11586
177. Gobeske KT et al (2009) BMP signaling mediates effects of exercise on hippocampal neurogenesis and cognition in mice. PLoS One 4(10):e7506
178. Gohil K, Brooks GA (2012) Exercise tames the wild side of the Myc network: a hypothesis. Am J Physiol Endocrinol Metab 303(1):E18-E30
179. Littbrand H, Stenvall M, Rosendahl E (2011) Applicability and effects of physical exercise on physical and cognitive functions and activities of daily living among people with dementia: a systematic review. Am J Phys Med Rehabil 90(6):495-518
180. Solfrizzi V, Panza F, Capurso A (2003) The role of diet in cognitive decline. J Neural Transm 110(1):95-110
181. Joseph JA et al (2005) Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res 30(6-7):927-935
182. Brayne C et al (2010) Education, the brain and dementia: neuroprotection or compensation? Brain 133(Pt 8):2210-2216
183. Whalley LJ et al (2004) Cognitive reserve and the neurobiology of cognitive aging. Ageing Res Rev 3(4):369-382
184. Hooli BV et al (2012) Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78(16):1250-1257
185. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-356
186. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3(1):75-80
187. Chavez-Gutierrez L et al (2012) The mechanism of gamma-secretase dysfunction in familial Alzheimer disease. EMBO J 31(10):2261-2274
188. Rubinsztein DC et al (1999) Apo E genotypes and risk of dementia in Down syndrome. Am J Med Genet 88(4):344-347
189. McNaughton D et al (2012) Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol Aging 33(2):426, e13-21
190. Rovelet-Lecrux A et al (2007) APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 78(10):1158-1159
191. Cabrejo L et al (2006) Phenotype associated with APP duplication in five families. Brain 129(Pt 11):2966-2976
192. Lleo A et al (2003) Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression. J Biol Chem 278(48):47370-47375
193. Kinoshita A et al (2003) The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe65. J Biol Chem 278(42):41182-41188
194. Lammich S et al (2002) Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 277(47):44754-44759
195. Shen J, Kelleher RJ III (2007) The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 104(2):403-409
196. Roemer K (2012) Notch and the p53 clan of transcription factors. Adv Exp Med Biol 727:223-240
197. Roncarati R et al (2002) The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. Proc Natl Acad Sci U S A 99(10):7102-7107
198. Fassa A, Mehta P, Efthimiopoulos S (2005) Notch 1 interacts with the amyloid precursor protein in a Numb-independent manner. J Neurosci Res 82(2):214-224
199. Kyriazis GA et al (2008) Numb endocytic adapter proteins regulate the transport and processing of the amyloid precursor protein in an isoform-dependent manner: implications for Alzheimer disease pathogenesis. J Biol Chem 283(37):25492-25502
200. Hartmann D et al (2001) Implication of APP secretases in notch signaling. J Mol Neurosci 17(2):171-181
201. Woo HN et al (2009) Alzheimer's disease and Notch signaling. Biochem Biophys Res Commun 390(4):1093-1097
202. Walton M et al (1998) Do c-Jun, c-Fos, and amyloid precursor protein play a role in neuronal death or survival? J Neurosci Res 53(3):330-342
203. De Ferrari GV, Moon RT (2006) The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25(57):7545-7553
204. Boonen RA, van Tijn P, Zivkovic D (2009) Wnt signaling in Alzheimer's disease: up or down, that is the question. Ageing Res Rev 8(2):71-82
205. Li F, Chong ZZ, Maiese K (2005) Vital elements of the Wnt-Frizzled signaling pathway in the nervous system. Curr Neurovasc Res 2(4):331-340
206. Chong ZZ, Maiese K (2004) Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol 19(2):495-504
207. Caricasole A et al (2005) Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci Rep 25(5-6):309-327
208. Chong ZZ, Li F, Maiese K (2005) Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 49(1):1-21
209. Toledo EM, Colombres M, Inestrosa NC (2008) Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 86(3):281-296
210. Behrens MI, Lendon C, Roe CM (2009) A common biological mechanism in cancer and Alzheimer's disease? Curr Alzheimer Res 6(3):196-204
211. Meredith JE Jr et al (2002) Gamma-secretase activity is not involved in presenilin-mediated regulation of beta-catenin. Biochem Biophys Res Commun 299(5):744-750
212. Killick R et al (2001) Presenilin 1 independently regulates beta-catenin stability and transcriptional activity. J Biol Chem 276(51):48554-48561
213. Magdesian MH et al (2008) Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283(14):9359-9368
214. Chen Y, Bodles AM (2007) Amyloid precursor protein modulates beta-catenin degradation. J Neuroinflammation 4:29
215. De Jonghe C et al (2001) Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet 10(16):1665-1671
216. van Helmond Z et al (2010) Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 20(2):468-480
217. Furukawa K et al (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 67(5):1882-1896
218. Lee DH, Wang HY (2003) Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. J Neurobiol 55(1):25-30
219. Zou K et al (2003) Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87(3):609-619
220. Shankar GM et al (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 36(2):293-302
221. Puzzo D, Arancio O (2013) Amyloid-beta peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis 33(Suppl 1):S111-S120
222. Castellani RJ et al (2006) Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen 21(2):126-130
223. Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36(12):1307-1313
224. Van Nostrand WE et al (2001) Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J Biol Chem 276(35):32860-32866
225. Murakami K et al (2002) Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23. Biochem Biophys Res Commun 294(1):5-10
226. Tsubuki S, Takaki Y, Saido TC (2003) Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361(9373):1957-1958
227. Morelli L et al (2003) Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem 278(26):23221-23226
228. De Jonghe C et al (1998) Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis 5(4):281-286
229. van Duinen SG et al (1995) Cortical tissue of patients with hereditary cerebral hemorrhage with amyloidosis (Dutch) contains various extracellular matrix deposits. Lab Investig 73(2):183-189
230. Van Nostrand WE et al (2002) Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. Ann N Y Acad Sci 977:258-265
231. Larner AJ, Doran M (2009) Genotype-phenotype relationships of presenilin-1 mutations in Alzheimer's disease: an update. J Alzheimers Dis 17(2):259-265
232. Bentahir M et al (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96(3):732-742
233. Lee J, Chan SL, Mattson MP (2002) Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromol Med 2(1):29-45
234. Heilig EA et al (2010) A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. J Biol Chem 285(29):22350-22359
235. Maarouf CL et al (2008) Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener 3:20
236. Shepherd C, McCann H, Halliday GM (2009) Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol 118(1):37-52
237. Jonsson T et al (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488(7409):96-99
238. Lathia JD, Mattson MP, Cheng A (2008) Notch: from neural development to neurological disorders. J Neurochem 107(6):1471-1481
239. Cairney CJ et al (2009) A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging. Biochim Biophys Acta 1792(4):353-363
240. Liu ZJ et al (2012) Notch activation induces endothelial cell senescence and pro-inflammatory response: implication of Notch signaling in atherosclerosis. Atherosclerosis 225(2):296-303
241. Stefani M, Liguri G (2009) Cholesterol in Alzheimer's disease: unresolved questions. Curr Alzheimer Res 6(1):15-29
242. Polazzi E, Monti B (2010) Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol 92(3):293-315
243. Aguzzi A, Barres BA, Bennett ML (2013) Microglia: scapegoat, saboteur, or something else? Science 339(6116):156-161
244. Moreira PI et al (2005) A second look into the oxidant mechanisms in Alzheimer's disease. Curr Neurovasc Res 2(2):179-184
245. Driver JA, Lu KP (2010) Pin1: a new genetic link between Alzheimer's disease, cancer and aging. Curr Aging Sci 3(3):158-165
246. Arendt T (1993) Neuronal dedifferentiation and degeneration in Alzheimer's disease. Biol Chem 374:911-912
247. Arendt T (2005) Cell cycle activation in neurons - the final exit of brain morpho-dysregulation. In: Copani A, Nicoletti F (eds) Cell cycle mechanisms in neuronal cell death. Landes Bioscience and Kluwer Academic, Georgetown, pp 1-21
248. Blass JP (2002) Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol Aging 23(6):1077-1084
249. Mc Donald JM et al (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133(Pt 5):1328-1341
250. Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 24(1):1-23
251. Joseph J et al (2001) Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging 22(1):131-146
252. Lee EB, Lee VM, Trojanowski JQ (2012) Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 13(1):38-50